BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 43.0] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Zhang W, Shi B, Chen G, Zheng Y, An Y, Sun M, Feng Y, Shang Q, Zhang X. Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B. Medicine (Baltimore) 2021;100:e27220. [PMID: 34664859 DOI: 10.1097/MD.0000000000027220] [Reference Citation Analysis]
2 Cheng M, Zhu Z, Ye S, Chen J, Dong X, Gao G. Clinical Value of Plasma Secreted Frizzled-Related Protein 4 in the Chronic Hepatitis B Virus Infection: A Cross-sectional Study. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.116525] [Reference Citation Analysis]
3 Cui D, Jiang D, Yan C, Liu X, Lv Y, Xie J, Chen Y. Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative. Front Microbiol 2022;13:887408. [PMID: 35572697 DOI: 10.3389/fmicb.2022.887408] [Reference Citation Analysis]
4 Beyaz Coşkun A, Sağdiçoğlu Celep AG. Therapeutic modulation methods of gut microbiota and gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 33749411 DOI: 10.1080/10408398.2021.1902263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
6 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
7 Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
8 Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2021:gutjnl-2021-324646. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
9 Schulze RJ, Schott MB, Casey CA, Tuma PL, McNiven MA. The cell biology of the hepatocyte: A membrane trafficking machine. J Cell Biol 2019;218:2096-112. [PMID: 31201265 DOI: 10.1083/jcb.201903090] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
10 Gong S, Zhang S, Wang X, Li J, Pan W, Li N, Tang B. Strand Displacement Amplification Assisted CRISPR-Cas12a Strategy for Colorimetric Analysis of Viral Nucleic Acid. Anal Chem 2021;93:15216-23. [PMID: 34736322 DOI: 10.1021/acs.analchem.1c04133] [Reference Citation Analysis]
11 Yll M, Cortese MF, Guerrero-Murillo M, Orriols G, Gregori J, Casillas R, González C, Sopena S, Godoy C, Vila M, Tabernero D, Quer J, Rando A, Lopez-Martinez R, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F. Conservation and variability of hepatitis B core at different chronic hepatitis stages. World J Gastroenterol 2020; 26(20): 2584-2598 [PMID: 32523313 DOI: 10.3748/wjg.v26.i20.2584] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yuen MF, Wong DK, Schluep T, Lai CL, Ferrari C, Locarnini S, Lo RC, Gish RG, Hamilton J, Wooddell CI, Mak LY, Given BD. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut 2022;71:789-97. [PMID: 33712437 DOI: 10.1136/gutjnl-2020-323445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
13 Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med 2022;9:859430. [DOI: 10.3389/fmed.2022.859430] [Reference Citation Analysis]
14 Wu Y, Wen J, Tang G, Zhang J, Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B. J Infect 2021;83:594-600. [PMID: 34474058 DOI: 10.1016/j.jinf.2021.08.044] [Reference Citation Analysis]
15 Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2021. [PMID: 34002067 DOI: 10.1038/s41577-021-00549-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
16 Jiang D, Chen C, Yan D, Zhang X, Liu X, Yan D, Cui D, Yang S. Exhausted phenotype of circulating CD8+ T cell subsets in hepatitis B virus carriers. BMC Immunol 2022;23:18. [PMID: 35443611 DOI: 10.1186/s12865-022-00488-2] [Reference Citation Analysis]
17 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, Cheung KS, Yuen MF, Seto WK. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 2021;15:901-11. [PMID: 34152534 DOI: 10.1007/s12072-021-10218-2] [Reference Citation Analysis]
18 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
19 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
21 Na YG, Kim M, Han M, Huh HW, Kim JS, Kim JC, Park JH, Lee HK, Cho CW. Characterization of Hepatitis B Surface Antigen Loaded Polylactic Acid-Based Microneedle and Its Dermal Safety Profile. Pharmaceutics 2020;12:E531. [PMID: 32527003 DOI: 10.3390/pharmaceutics12060531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Muraleedharan A, Bupesh G. A short note on HBV infection. Bioinformation 2020;16:505-8. [PMID: 32994674 DOI: 10.6026/97320630016505] [Reference Citation Analysis]
23 Blanco-Rodriguez G, Di Nunzio F. The Viral Capsid: A Master Key to Access the Host Nucleus. Viruses 2021;13:1178. [PMID: 34203080 DOI: 10.3390/v13061178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sun Z, Qiao D, Shi Y, Barz M, Liu L, Chen Y. Precision Wormlike Nanoadjuvant Governs Potency of Vaccination. Nano Lett 2021;21:7236-43. [PMID: 34459617 DOI: 10.1021/acs.nanolett.1c02274] [Reference Citation Analysis]
25 Peliganga LB, Mello VM, de Sousa PSF, Horta MAP, Soares ÁD, Nunes JPDS, Nobrega M, Lewis-Ximenez LL. Transfusion Transmissible Infections in Blood Donors in the Province of Bié, Angola, during a 15-Year Follow-Up, Imply the Need for Pathogen Reduction Technologies. Pathogens 2021;10:1633. [PMID: 34959588 DOI: 10.3390/pathogens10121633] [Reference Citation Analysis]
26 Tu F, Yang R, Wang W, Li R, Du G, Liu Y, Li W, Wei P. Analysis of Knowledge, Attitude and Practice of Hepatitis B Among Freshmen in Jiangsu Based on Lasso-Logistic Regression and Structural Equation Model. Infect Drug Resist 2022;15:3063-73. [PMID: 35734538 DOI: 10.2147/IDR.S365728] [Reference Citation Analysis]
27 Darshani P, Sen Sarma S, Srivastava AK, Baishya R, Kumar D. Anti-viral triterpenes: a review. Phytochem Rev. [DOI: 10.1007/s11101-022-09808-1] [Reference Citation Analysis]
28 Yeh ML, Liang PC, Huang CI, Hsieh MH, Lin YH, Jang TY, Wei YJ, Hsu PY, Hsu CT, Wang CW, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. J Gastroenterol Hepatol 2021. [PMID: 34318943 DOI: 10.1111/jgh.15640] [Reference Citation Analysis]
29 Zakrzewicz D, Leidolf R, Kunz S, Müller SF, Neubauer A, Leiting S, Goldmann N, Lehmann F, Glebe D, Geyer J. Tyrosine 146 of the Human Na+/Taurocholate Cotransporting Polypeptide (NTCP) Is Essential for Its Hepatitis B Virus (HBV) Receptor Function and HBV Entry into Hepatocytes. Viruses 2022;14:1259. [PMID: 35746730 DOI: 10.3390/v14061259] [Reference Citation Analysis]
30 Yin M, Xiong Y, Liang D, Tang H, Hong Q, Liu G, Zeng J, Lian T, Huang J, Ni J. Circulating Tfh cell and subsets distribution are associated with low-responsiveness to hepatitis B vaccination. Mol Med 2021;27:32. [PMID: 33794763 DOI: 10.1186/s10020-021-00290-7] [Reference Citation Analysis]
31 Waller KM, De La Mata NL, Kelly PJ, Ramachandran V, Rawlinson WD, Wyburn KR, Webster AC. Residual risk of infection with blood-borne viruses in potential organ donors at increased risk of infection: systematic review and meta-analysis. Med J Aust 2019;211:414-20. [PMID: 31489635 DOI: 10.5694/mja2.50315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
32 Lai X, Chen W, Wu Y, Gao Y, Zhang Y, Xu X, Fu Y, Wang X, Yang Y, Zhang Y. Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients. J Clin Lab Anal 2022;:e24530. [PMID: 35657116 DOI: 10.1002/jcla.24530] [Reference Citation Analysis]
33 Srisuwarn P, Sumethkul V. Kidney transplant from donors with hepatitis B: A challenging treatment option. World J Hepatol 2021; 13(8): 853-867 [PMID: 34552692 DOI: 10.4254/wjh.v13.i8.853] [Reference Citation Analysis]
34 Yu C, Sun Y, Xu L, Zhang X, Liu K, Jin J, Huang X, Wang Y. Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2021;27:668.e1-9. [PMID: 34052506 DOI: 10.1016/j.jtct.2021.05.015] [Reference Citation Analysis]
35 Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol 2021;362:104283. [PMID: 33548734 DOI: 10.1016/j.cellimm.2021.104283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zaongo SD, Ouyang J, Chen Y, Jiao Y, Wu H, Chen Y. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Front Immunol 2022;13:853346. [DOI: 10.3389/fimmu.2022.853346] [Reference Citation Analysis]
38 Kremsdorf D, Lekbaby B, Bablon P, Sotty J, Augustin J, Schnuriger A, Pol J, Soussan P. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021;70:2373-82. [PMID: 34535538 DOI: 10.1136/gutjnl-2021-324554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
39 Yu W, Hu X, Cao B. Viral Infections During Pregnancy: The Big Challenge Threatening Maternal and Fetal Health. Maternal-Fetal Medicine 2022;4:72-86. [DOI: 10.1097/fm9.0000000000000133] [Reference Citation Analysis]
40 Jasinski-bergner S, Schmiedel D, Mandelboim O, Seliger B. Role of HLA-G in Viral Infections. Front Immunol 2022;13:826074. [DOI: 10.3389/fimmu.2022.826074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Funato K, Otsuka M, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, Fujishiro M. Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors. Biochemical and Biophysical Research Communications 2022;607:89-95. [DOI: 10.1016/j.bbrc.2022.03.137] [Reference Citation Analysis]
42 Cruz LAB, Moraes MOA, Queiroga-Barros MR, Fukutani KF, Barral-Netto M, Andrade BB. Chronic hepatitis B virus infection drives changes in systemic immune activation profile in patients coinfected with Plasmodium vivax malaria. PLoS Negl Trop Dis 2019;13:e0007535. [PMID: 31233500 DOI: 10.1371/journal.pntd.0007535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
43 Jiang W, Wang L, Zhang Y, Li H. Circ-ATP5H Induces Hepatitis B Virus Replication and Expression by Regulating miR-138-5p/TNFAIP3 Axis. Cancer Manag Res 2020;12:11031-40. [PMID: 33173336 DOI: 10.2147/CMAR.S272983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Xie X, Lv H, Liu C, Su X, Yu Z, Song S, Bian H, Tian M, Qin C, Qi J, Zhu Q. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis. BMC Med 2021;19:247. [PMID: 34649530 DOI: 10.1186/s12916-021-02085-3] [Reference Citation Analysis]
45 Lau KCK, Joshi SS, Mahoney DJ, Mason AL, van Marle G, Osiowy C, Coffin CS. Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants. Front Microbiol 2020;11:1653. [PMID: 32760388 DOI: 10.3389/fmicb.2020.01653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Chen XF, Zhao X, Yang Z. Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. J Med Chem 2021;64:17601-26. [PMID: 34854680 DOI: 10.1021/acs.jmedchem.1c01567] [Reference Citation Analysis]
47 Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses 2020;12:E126. [PMID: 31973017 DOI: 10.3390/v12020126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
48 Lou Z, Zhou R, Su Y, Liu C, Ruan W, Jeon CO, Han X, Lin C, Jia B. Minor and major circRNAs in virus and host genomes. J Microbiol 2021;59:324-31. [DOI: 10.1007/s12275-021-1021-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Guzmán-Solís AA, Villa-Islas V, Bravo-López MJ, Sandoval-Velasco M, Wesp JK, Gómez-Valdés JA, Moreno-Cabrera ML, Meraz A, Solís-Pichardo G, Schaaf P, tenOever BR, Blanco-Melo D, Ávila Arcos MC. Ancient viral genomes reveal introduction of human pathogenic viruses into Mexico during the transatlantic slave trade. Elife 2021;10:e68612. [PMID: 34350829 DOI: 10.7554/eLife.68612] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Suresh M, Li B, Huang X, Korolowicz KE, Murreddu MG, Gudima SO, Menne S. Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects. Front Immunol 2021;12:745802. [PMID: 34671360 DOI: 10.3389/fimmu.2021.745802] [Reference Citation Analysis]
52 Le C, Liu Y, López-Orozco J, Joyce MA, Le XC, Tyrrell DL. CRISPR Technique Incorporated with Single-Cell RNA Sequencing for Studying Hepatitis B Infection. Anal Chem 2021;93:10756-61. [PMID: 34328316 DOI: 10.1021/acs.analchem.1c02227] [Reference Citation Analysis]
53 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zong Z, Liu J, Wang N, Yang C, Wang Q, Zhang W, Chen Y, Liu X, Deng H. Nicotinamide mononucleotide inhibits hepatic stellate cell activation to prevent liver fibrosis via promoting PGE2 degradation. Free Radic Biol Med 2021;162:571-81. [PMID: 33220424 DOI: 10.1016/j.freeradbiomed.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
56 Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection. Hepatology Communications. [DOI: 10.1002/hep4.1951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mohammadzadeh I, Qujeq D, Yousefi T, Ferns GA, Maniati M, Vaghari-Tabari M. CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life. 2020;72:1603-1621. [PMID: 32344465 DOI: 10.1002/iub.2296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
58 Yang E, Li MMH. All About the RNA: Interferon-Stimulated Genes That Interfere With Viral RNA Processes. Front Immunol 2020;11:605024. [PMID: 33362792 DOI: 10.3389/fimmu.2020.605024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
59 Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, Michel ML, Protzer U, Knolle PA. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Sci Rep 2019;9:10808. [PMID: 31346211 DOI: 10.1038/s41598-019-47149-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
60 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
61 Zheng B, Yu Y, Pan Z, Feng Y, Zhao H, Han Q, Zhang J. HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients. Int J Mol Sci 2021;22:7643. [PMID: 34299262 DOI: 10.3390/ijms22147643] [Reference Citation Analysis]
62 Zhang L. Autophagy in hepatitis B or C virus infection: An incubator and a potential therapeutic target. Life Sciences 2020;242:117206. [DOI: 10.1016/j.lfs.2019.117206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Ivics Z, Amberger M, Zahn T, Hildt E. [Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on CAR T cells]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1357-64. [PMID: 32995895 DOI: 10.1007/s00103-020-03223-7] [Reference Citation Analysis]
64 Wei J, Shi Y, Zou C, Zhang H, Peng H, Wang S, Xia L, Yang Y, Zhang X, Liu J, Zhou H, Luo M, Huang A, Wang D. Cellular Id1 inhibits hepatitis B virus transcription by interacting with the novel covalently closed circular DNA-binding protein E2F4. Int J Biol Sci 2022;18:65-81. [PMID: 34975318 DOI: 10.7150/ijbs.62106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zhu Q, Pan QZ, Zhong AL, Hu H, Zhao JJ, Tang Y, Hu WM, Li M, Weng DS, Chen MY, Ma G, Xia JC. Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. Int Immunopharmacol 2020;89:107139. [PMID: 33191179 DOI: 10.1016/j.intimp.2020.107139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Wooddell CI, Gehring AJ, Yuen MF, Given BD. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses 2021;13:581. [PMID: 33808298 DOI: 10.3390/v13040581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Reference Citation Analysis]
68 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ding Z, Dong Z, Chen Z, Hong J, Yan L, Li H, Yao S, Yan Y, Yang Y, Yang C, Li T. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Front Immunol 2021;12:733530. [PMID: 34659220 DOI: 10.3389/fimmu.2021.733530] [Reference Citation Analysis]
70 Silva RJS, do Nascimento RS, Oliveira-Neto JAJ, Silva FQ, Piauiense JNF, Gomes CM, Pinheiro LML, Resque RL, Pinho JRR, Kupek E, Fischer B, Machado LFA, Martins LC, Lemos JAR, Oliveira-Filho AB. Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region. Viruses 2021;13:1380. [PMID: 34372586 DOI: 10.3390/v13071380] [Reference Citation Analysis]
71 Zhou Z, Zhou Z, Huang Z, He S, Chen S. Histone-fold centromere protein W (CENP-W) is associated with the biological behavior of hepatocellular carcinoma cells. Bioengineered 2020;11:729-42. [PMID: 32635817 DOI: 10.1080/21655979.2020.1787776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
72 Yang L, Zhang Y, Zhang K, Liu Z, He T, Zheng X, Li L, Arnér ESJ, Zhang Z, Zhang J. Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease. EClinicalMedicine 2021;42:101180. [PMID: 34765954 DOI: 10.1016/j.eclinm.2021.101180] [Reference Citation Analysis]
73 Villar LM, Bezerra CS, Cruz HM, Portilho MM, Flores GL. Applicability of Oral Fluid and Dried Blood Spot for Hepatitis B Virus Diagnosis. Can J Gastroenterol Hepatol. 2019;2019:5672795. [PMID: 31058110 DOI: 10.1155/2019/5672795] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
74 Papadopoulos N, Gkavogiannakis N, Panagakou S, Papadatos G, Panagoulis E, Deutsch M, Liaskonis K, German V. Prevalence of Hepatitis B Serum Markers in Young Military Recruits in Greece: A Comparison Study between 2005 and 2019 Cohorts. Livers 2021;1:230-5. [DOI: 10.3390/livers1040018] [Reference Citation Analysis]
75 Thi EP, Dhillon AP, Ardzinski A, Bidirici-Ertekin L, Cobarrubias KD, Cuconati A, Kondratowicz AS, Kwak K, Li AHL, Miller A, Pasetka C, Pei L, Phelps JR, Snead NM, Wang X, Ye X, Sofia MJ, Lee ACH. ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. ACS Infect Dis 2019;5:725-37. [PMID: 30403127 DOI: 10.1021/acsinfecdis.8b00191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
76 Sheng X, Zhou J, Gu X, Wang H, Li C. The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/3451544] [Reference Citation Analysis]
77 Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J. Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences. Int J Mol Sci 2022;23:2787. [PMID: 35269929 DOI: 10.3390/ijms23052787] [Reference Citation Analysis]
78 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Xie J, Chen C, Hou LJ, Zhou CJ, Fang L, Chen JJ. Dual Metabolomic Platforms Identified a Novel Urinary Metabolite Signature for Hepatitis B Virus-Infected Patients with Depression. Diabetes Metab Syndr Obes 2020;13:1677-83. [PMID: 32547129 DOI: 10.2147/DMSO.S251034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Tu Y, Chen D, Pan T, Chen Z, Xu J, Jin L, Sheng L, Jin X, Wang X, Lan X, Ge Y, Sun H, Chen Y. Inhibition of miR-431-5p attenuated liver apoptosis through KLF15/p53 signal pathway in S100 induced autoimmune hepatitis mice. Life Sci 2021;280:119698. [PMID: 34111466 DOI: 10.1016/j.lfs.2021.119698] [Reference Citation Analysis]
81 Lu Y, Zhou C, Yan R, Lian J, Cai H, Yu J, Chen D, Su X, Qian J, Yang Y, Li L. Dynamic metabolic profiles for HBeAg seroconversion in chronic hepatitis B (CHB) patients by gas chromatography-mass spectrometry (GC-MS). J Pharm Biomed Anal 2021;206:114349. [PMID: 34597840 DOI: 10.1016/j.jpba.2021.114349] [Reference Citation Analysis]
82 Colón-Thillet R, Jerome KR, Stone D. Optimization of AAV vectors to target persistent viral reservoirs. Virol J 2021;18:85. [PMID: 33892762 DOI: 10.1186/s12985-021-01555-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
84 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
85 Jo E, Yang J, Koenig A, Yoon SK, Windisch MP. A Simple and Cost-Effective DNA Preparation Method Suitable for High-Throughput PCR Quantification of Hepatitis B Virus Genomes. Viruses 2020;12:E928. [PMID: 32846983 DOI: 10.3390/v12090928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Zhang K, Lin S, Wang M, Huang J, Zhu Y. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. Biomed Res Int 2020;2020:5728359. [PMID: 32596332 DOI: 10.1155/2020/5728359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Wei L, Ploss A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 2021;13:1463. [PMID: 34452329 DOI: 10.3390/v13081463] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Higashi-Kuwata N, Hayashi S, Kumamoto H, Ogata-Aoki H, Das D, Venzon D, Hattori SI, Bulut H, Hashimoto M, Otagiri M, Takamune N, Kishimoto N, Davis DA, Misumi S, Kakuni M, Tanaka Y, Mitsuya H. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. J Hepatol 2021;74:1075-86. [PMID: 33333207 DOI: 10.1016/j.jhep.2020.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Jiao Q, Xu W, Guo X, Liu H, Liao B, Zhu X, Chen C, Yang F, Wu L, Xie C, Peng L. NLRX1 can counteract innate immune response induced by an external stimulus favoring HBV infection by competitive inhibition of MAVS-RLRs signaling in HepG2-NTCP cells. Sci Prog 2021;104:368504211058036. [PMID: 34825857 DOI: 10.1177/00368504211058036] [Reference Citation Analysis]
90 Ho E, Van Hees S, Goethals S, Smits E, Huizing M, Francque S, De Winter B, Michielsen P, Vanwolleghem T. Biobanking for Viral Hepatitis Research. Front Med (Lausanne) 2019;6:183. [PMID: 31482092 DOI: 10.3389/fmed.2019.00183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2021. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
92 Arefkhah N, Vafazadeh S, Shahriarirad S, Ghorbani F, Zoghi S, Emami M, Zamiri B, Cheraghi MR, Sarvari J, Sarkari B. Serum levels of anti-hepatitis B surface antibodies among vaccinated children aged 1 to 12 years in a rural community in Fars Province, southern Iran. J Immunoassay Immunochem 2020;41:20-7. [PMID: 31590597 DOI: 10.1080/15321819.2019.1675696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
93 Mathkar PP, Chen X, Sulovari A, Li D. Characterization of Hepatitis B Virus Integrations Identified in Hepatocellular Carcinoma Genomes. Viruses 2021;13:245. [PMID: 33557409 DOI: 10.3390/v13020245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, Zhu Y, Ye Y, Huang Y, Fu S, Huang H, Luo Y. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:956-64. [PMID: 31962163 DOI: 10.1016/j.bbmt.2020.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Tang R, Lei Z, Wang X, Qi Q, He J, Liu D, Wang X, Chen X, Zhu J, Li Y, Zhou S, Su C. Hepatitis B envelope antigen increases Tregs by converting CD4+CD25- T cells into CD4+CD25+Foxp3+ Tregs. Exp Ther Med 2020;20:3679-86. [PMID: 32855720 DOI: 10.3892/etm.2020.9107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
96 Xu R, Song D, Wang M, Huang J, Liao Q, Shan Z, Rong X, Fu Y. Molecular Epidemiological Characteristics and Risk Factors for Acquiring HBV Among Li Ethnic in Baisha County, Hainan Island-Subgenotype D3 Was First Discovered in China. Front Microbiol 2022;13:837746. [DOI: 10.3389/fmicb.2022.837746] [Reference Citation Analysis]
97 Simionescu AA, Streinu-Cercel A, Popescu FD, Stanescu AMA, Vieru M, Danciu BM, Miron VD, Săndulescu O. Comprehensive Overview of Vaccination during Pregnancy in Europe. J Pers Med 2021;11:1196. [PMID: 34834548 DOI: 10.3390/jpm11111196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Balzarini M, Kodadek T. A "Smart Lock" for Preventing Hepatitis B Entry into Cells. Cell Chem Biol 2018;25:804-6. [PMID: 30028974 DOI: 10.1016/j.chembiol.2018.06.011] [Reference Citation Analysis]
99 Suwanpakdee D, Taweesith W, Traivaree C, Rujkijyanont P. HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors. Glob Pediatr Health 2021;8:2333794X211033452. [PMID: 34350309 DOI: 10.1177/2333794X211033452] [Reference Citation Analysis]
100 Roca Suarez AA, Testoni B, Baumert TF, Lupberger J. Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Front Immunol 2020;11:624034. [PMID: 33613561 DOI: 10.3389/fimmu.2020.624034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 El-Nabi SH, El-Garawani I, Ismail F, Abdelsameea E. Anti-HBc and hepatitis B virus DNA among HBsAg-negative blood donors from the main central blood bank units in Eastern Libya. Transfus Med 2020;30:401-5. [PMID: 32894893 DOI: 10.1111/tme.12711] [Reference Citation Analysis]
102 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
104 Mohsin DH, Mashkour MS, Fatemi F. Design of aptamer-based sensing platform using gold nanoparticles functionalized reduced graphene oxide for ultrasensitive detection of Hepatitis B virus. Chem Pap 2021;75:279-95. [DOI: 10.1007/s11696-020-01292-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
105 Zhao T, Qi J, Liu T, Wu H, Zhu Q. N6-Methyladenosine Modification Participates in the Progression of Hepatitis B Virus-Related Liver Fibrosis by Regulating Immune Cell Infiltration. Front Med (Lausanne) 2022;9:821710. [PMID: 35308519 DOI: 10.3389/fmed.2022.821710] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020; 26(9): 883-903 [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
107 Li X, Xu Z, Mitra B, Wang M, Guo H, Feng Z. Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells. Cell Biosci 2021;11:123. [PMID: 34225786 DOI: 10.1186/s13578-021-00641-1] [Reference Citation Analysis]
108 Medhasi S, Chantratita N, Ciccacci C. Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9710376] [Reference Citation Analysis]
109 Duan L, Yang Q, Yang J, Hu Q, Wang B, Li P, Chen W. Identification of serum β-catenin as a biomarker in patients with HBV-related liver diseases. J Transl Med 2018;16:265. [PMID: 30268125 DOI: 10.1186/s12967-018-1645-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
110 Le DT, Müller KM. In Vitro Assembly of Virus-Like Particles and Their Applications. Life (Basel) 2021;11:334. [PMID: 33920215 DOI: 10.3390/life11040334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Ruan L, Huang L, Zhao L, Wang Q, Pan X, Zhang A, Bai Q, Lv Z. The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients. Gastroenterol Res Pract 2018;2018:9187316. [PMID: 30622563 DOI: 10.1155/2018/9187316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
112 Huang H, Huang HC, Chiou WC, Lin LC, Chen JC, Liu HK, Lai YH, Huang C. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP. Antiviral Res 2021;195:105184. [PMID: 34627935 DOI: 10.1016/j.antiviral.2021.105184] [Reference Citation Analysis]
113 Teixeira TA, Oliveira YC, Bernardes FS, Kallas EG, Duarte-Neto AN, Esteves SC, Drevet JR, Hallak J. Viral infections and implications for male reproductive health. Asian J Androl 2021;23:335-47. [PMID: 33473014 DOI: 10.4103/aja.aja_82_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
115 Liu J, Zhao H, Zhou X, He Y, Chen Q. Antiviral activities of Janus-type nucleosides and their related oxime-intermediates. Bioorg Med Chem 2019;27:2332-9. [PMID: 30578076 DOI: 10.1016/j.bmc.2018.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
116 Yu T, Zhang S, Matei R, Marx W, Beisel CL, Wei Q. Coupling smartphone and CRISPR–Cas12a for digital and multiplexed nucleic acid detection. AIChE J 2021;67. [DOI: 10.1002/aic.17365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
117 Wang L, Shi C, Yu J, Xu Y. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-021-02372-2] [Reference Citation Analysis]
118 Liu C, Zheng Y, Li X, Li B, Wen L, Wang D, Feng Q, Jiang C. Study on the Expression Differences and the Correlation with H2BE Gene of Th Related Cytokines in SSDHS and LDSDS TCM-Syndromes of CHB Patients. Evid Based Complement Alternat Med 2021;2021:6291428. [PMID: 33688361 DOI: 10.1155/2021/6291428] [Reference Citation Analysis]
119 Kohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J. Human hepatitis D virus-specific T cell epitopes. JHEP Rep 2021;3:100294. [PMID: 34308324 DOI: 10.1016/j.jhepr.2021.100294] [Reference Citation Analysis]
120 Zhao D, Zhang H, Cao Q, Wang Z, Zhang R. The research of SARIMA model for prediction of hepatitis B in mainland China. Medicine (Baltimore) 2022;101:e29317. [PMID: 35687775 DOI: 10.1097/MD.0000000000029317] [Reference Citation Analysis]
121 Cheng HR, Yang HC, Lin SR, Yang TY, Lin YY, Su TH, Tseng TC, Liu CJ, Kao JH. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Hepatol Int 2021;15:582-92. [PMID: 33886088 DOI: 10.1007/s12072-021-10186-7] [Reference Citation Analysis]
122 Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. J Gastroenterol Hepatol 2020;35:1774-81. [PMID: 32154938 DOI: 10.1111/jgh.15031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
123 Kim D, Lee YS, Jung SJ, Yeo J, Seo JJ, Lee YY, Lim J, Chang H, Song J, Yang J, Kim JS, Jung G, Ahn K, Kim VN. Viral hijacking of the TENT4-ZCCHC14 complex protects viral RNAs via mixed tailing. Nat Struct Mol Biol 2020;27:581-8. [PMID: 32451488 DOI: 10.1038/s41594-020-0427-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
124 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
125 Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Reference Citation Analysis]
126 Gaglia MM, Munger K. More than just oncogenes: mechanisms of tumorigenesis by human viruses. Curr Opin Virol 2018;32:48-59. [PMID: 30268926 DOI: 10.1016/j.coviro.2018.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
127 Yu XQ, Zhang XX. Research progress in host immune response during hepatitis B virus infection. Chin Med J (Engl) 2020;133:2746-8. [PMID: 33009029 DOI: 10.1097/CM9.0000000000001096] [Reference Citation Analysis]
128 Zhao F, Xie X, Tan X, Yu H, Tian M, Lv H, Qin C, Qi J, Zhu Q. The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis. Front Immunol 2021;12:691766. [PMID: 34456908 DOI: 10.3389/fimmu.2021.691766] [Reference Citation Analysis]
129 Prescott NA, Bram Y, Schwartz RE, David Y. Targeting Hepatitis B Virus Covalently Closed Circular DNA and Hepatitis B Virus X Protein: Recent Advances and New Approaches. ACS Infect Dis 2019;5:1657-67. [PMID: 31525994 DOI: 10.1021/acsinfecdis.9b00249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
130 Lin J, Li J, Xie P, Han Y, Yu D, Chen J, Zhang X. Hepatitis B virus middle surface antigen loss promotes clinical variant persistence in mouse models. Virulence 2021;12:2868-82. [PMID: 34738866 DOI: 10.1080/21505594.2021.1999130] [Reference Citation Analysis]
131 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
132 Audsley J, Sasadeusz J. Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. Curr Opin HIV AIDS 2020;15:193-9. [PMID: 32141889 DOI: 10.1097/COH.0000000000000624] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Popa GL, Popa MI. Oxidative Stress in Chronic Hepatitis B—An Update. Microorganisms 2022;10:1265. [DOI: 10.3390/microorganisms10071265] [Reference Citation Analysis]
134 Moon IY, Kim JW. Methylation profile of hepatitis B virus is not influenced by interferon α in human liver cancer cells. Mol Med Rep 2021;24:715. [PMID: 34396432 DOI: 10.3892/mmr.2021.12354] [Reference Citation Analysis]
135 Vieira Barbosa J, Sahli R, Aubert V, Chaouch A, Moradpour D, Fraga M. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center. PLoS One 2021;16:e0250347. [PMID: 33905426 DOI: 10.1371/journal.pone.0250347] [Reference Citation Analysis]
136 Qiao D, Chen Y, Liu L. Engineered therapeutic nanovaccine against chronic hepatitis B virus infection. Biomaterials 2021;269:120674. [PMID: 33486345 DOI: 10.1016/j.biomaterials.2021.120674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Zhao Y, Baldin AV, Isayev O, Werner J, Zamyatnin AA Jr, Bazhin AV. Cancer Vaccines: Antigen Selection Strategy. Vaccines (Basel) 2021;9:85. [PMID: 33503926 DOI: 10.3390/vaccines9020085] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
138 Zeng Y, Xiao S, Yang L, Ma K, Shang H, Gao Y, Wang Y, Zhai F, Xiang R. Systematic analysis of the mechanism of Xiaochaihu decoction in hepatitis B treatment via network pharmacology and molecular docking. Comput Biol Med 2021;138:104894. [PMID: 34607274 DOI: 10.1016/j.compbiomed.2021.104894] [Reference Citation Analysis]
139 Hernández-Alvarez MI, Zorzano A. Mitochondrial Dynamics and Liver Cancer. Cancers (Basel) 2021;13:2571. [PMID: 34073868 DOI: 10.3390/cancers13112571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Giadans CG, Ríos DA, Ameigeiras B, Haddad L, De Matteo EN, Valva P, Preciado MV. Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same. J Viral Hepat 2021. [PMID: 34820942 DOI: 10.1111/jvh.13635] [Reference Citation Analysis]
142 Wu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Yang L, Huang H, Luo Y. A Novel Strategy for the Prevention of Hepatitis B Virus-Related Hepatitis Following Allogeneic Hematopoietic Stem Cell Transplantation from Hepatitis B Surface Antigen-Positive Donors. Biology of Blood and Marrow Transplantation 2020;26:1719-28. [DOI: 10.1016/j.bbmt.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
144 Wang L, Li L, Li C, Hou Y, Xu M, Yu Y, Ni X, Wang R, Wang H, Wang L, Peng J, Hou M. Significance of anti-HBc serological status in primary immune thrombocytopenia. Br J Haematol 2021. [PMID: 34854079 DOI: 10.1111/bjh.17977] [Reference Citation Analysis]
145 Mak LY, Huang Q, Wong DK, Stamm L, Cheung KS, Ko KL, Yan R, Ouyang L, Fung J, Seto WK, Yuen MF. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol 2021;56:479-88. [PMID: 33772643 DOI: 10.1007/s00535-021-01780-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Tang Y, Liu X, Lu X, He Q, Li G, Zou Y. Occult Hepatitis B Virus Infection in Maintenance Hemodialysis Patients: Prevalence and Mutations in "a" Determinant. Int J Med Sci 2020;17:2299-305. [PMID: 32922195 DOI: 10.7150/ijms.49540] [Reference Citation Analysis]
148 Shirmast P, Shahri MA, Pashangzadeh S, Mirshahabi H, Samadi E, Motamed N. Detection of occult hepatitis B virus in patients undergoing chemotherapy in Iran. Future Virology 2022;17:29-36. [DOI: 10.2217/fvl-2020-0386] [Reference Citation Analysis]
149 Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen HLA, Vanwolleghem T. Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion. J Viral Hepat 2019;26:766-9. [PMID: 30801868 DOI: 10.1111/jvh.13084] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
150 Zhou S, Li Y, Gao J, Wang Y, Ma X, Ding H, Li X, Sun S. Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. Bioengineered 2022;13:2851-65. [PMID: 35037840 DOI: 10.1080/21655979.2021.2024957] [Reference Citation Analysis]
151 Ferrando-Martinez S, Huang K, Bennett AS, Sterba P, Yu L, Suzich JA, Janssen HLA, Robbins SH. HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection. JHEP Rep 2019;1:170-8. [PMID: 32039367 DOI: 10.1016/j.jhepr.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
152 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
153 Hazari Y, Bravo-San Pedro JM, Hetz C, Galluzzi L, Kroemer G. Autophagy in hepatic adaptation to stress. J Hepatol. 2020;72:183-196. [PMID: 31849347 DOI: 10.1016/j.jhep.2019.08.026] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 47.0] [Reference Citation Analysis]
154 Audsley J, Avihingsanon A, Littlejohn M, Bowden S, Matthews GV, Fairley CK, Lewin SR, Sasadeusz J. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure? J Acquir Immune Defic Syndr 2020;84:527-33. [PMID: 32692112 DOI: 10.1097/QAI.0000000000002386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 Senaweera S, Du H, Zhang H, Kirby KA, Tedbury PR, Xie J, Sarafianos SG, Wang Z. Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. Viruses 2021;13:770. [PMID: 33925540 DOI: 10.3390/v13050770] [Reference Citation Analysis]
156 Li N, Zhong QQ, Yang XR, Wang QC, Zhang DT, Zheng S, Yang L, Wei WD. Prognostic Value of Hepatitis B Virus Infection in Very Young Patients With Curatively Resected Breast Cancer: Analyses From an Endemic Area in China. Front Oncol 2020;10:1403. [PMID: 32850453 DOI: 10.3389/fonc.2020.01403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
157 Revill PA, Lewin SR. Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. Curr Opin HIV AIDS 2020;15:151-6. [PMID: 32229770 DOI: 10.1097/COH.0000000000000620] [Reference Citation Analysis]
158 Nehme Z, Pasquereau S, Herbein G. Control of viral infections by epigenetic-targeted therapy. Clin Epigenetics 2019;11:55. [PMID: 30917875 DOI: 10.1186/s13148-019-0654-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
159 Tian T, Song C, Jiang L, Dai J, Lin Y, Xu X, Yu C, Ge Z, Ding Y, Wen Y, Liu B, Shao Y, Shi P, Zhu C, Liu Y, Jing S, Wang Z, Hu Z, Li J. Hepatitis B virus infection and the risk of cancer among the Chinese population. Int J Cancer 2020;147:3075-84. [PMID: 32478856 DOI: 10.1002/ijc.33130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
160 Cui J, Zhang N, Liu Y, Zhang L, Gao C, Liu S. Microarray gene expression profiling provides insights into functions of TIPE2 in HBV-related apoptosis. Mol Immunol 2021;131:137-43. [PMID: 33419563 DOI: 10.1016/j.molimm.2020.12.031] [Reference Citation Analysis]
161 Moon IY, Choi JH, Chung JW, Jang ES, Jeong SH, Kim JW. MicroRNA20 induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells. Mol Med Rep. 2019;20:2285-2293. [PMID: 31257511 DOI: 10.3892/mmr.2019.10435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
162 Liu X, Li D, Liu G. Cell membrane-derived biomimetic nanodecoys for viruses. Sci China Life Sci 2020;63:1254-6. [PMID: 32410090 DOI: 10.1007/s11427-020-1669-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
164 Yang J, Li Y, Ye J, Wang J, Lu H, Yao X. Characterization of the TCR β Chain Repertoire in Peripheral Blood from Hepatitis B Vaccine Responders and Non-Responders. JIR 2022;Volume 15:939-51. [DOI: 10.2147/jir.s347702] [Reference Citation Analysis]
165 Battagliotti JM, Fontana D, Etcheverrigaray M, Kratje R, Prieto C. Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein. Antiviral Res 2020;183:104936. [PMID: 32979402 DOI: 10.1016/j.antiviral.2020.104936] [Reference Citation Analysis]
166 Zhang Y, Zhao J, Cai J, Ye JC, Xiao YT, Mei Y, Zeng MS, Xie CM, Jiang Y, Feng GK. Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. Mol Imaging Biol 2020;22:864-72. [PMID: 31792839 DOI: 10.1007/s11307-019-01437-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, Zhang Y, Faiola F. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System. Front Pharmacol 2021;12:772768. [PMID: 35046808 DOI: 10.3389/fphar.2021.772768] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Bogolyubova AV. Human Oncogenic Viruses: Old Facts and New Hypotheses. Mol Biol 2019;53:767-75. [DOI: 10.1134/s0026893319050030] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer 2021;108:90-101. [PMID: 33358507 DOI: 10.1016/j.bulcan.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, Jin Y, Triyatni M, Lemenuel-Diot A, Cosson V, Xue Z, Kazma R, Bo Q. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2021;6:723-32. [PMID: 34237271 DOI: 10.1016/S2468-1253(21)00176-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
172 Bosso M, Kirchhoff F. Emerging Role of PYHIN Proteins as Antiviral Restriction Factors. Viruses 2020;12:E1464. [PMID: 33353088 DOI: 10.3390/v12121464] [Reference Citation Analysis]
173 Sun Y, Shi P, Wu Q, Liu B, Yu Z, Jia H, Chang H. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1. Hum Cell 2021. [PMID: 34273068 DOI: 10.1007/s13577-021-00577-1] [Reference Citation Analysis]
174 Auer ED, Tong HV, Amorim LM, Malheiros D, Hoan NX, Issler HC, Petzl-Erler ML, Beltrame MH, Boldt ABW, Toan NL, Song LH, Velavan TP, Augusto DG. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population. Int J Infect Dis 2020;96:541-7. [PMID: 32422377 DOI: 10.1016/j.ijid.2020.05.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
175 Guo X, Chen D, Cai Q, Huang Z, Xu W, Peng L, Chen P. Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line. BMC Mol Cell Biol. 2020;21:6. [PMID: 32070272 DOI: 10.1186/s12860-020-00250-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
176 Zeng X, Yuan X, Cai Q, Tang C, Gao J. Circular RNA as An Epigenetic Regulator in Chronic Liver Diseases. Cells 2021;10:1945. [PMID: 34440714 DOI: 10.3390/cells10081945] [Reference Citation Analysis]
177 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
178 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Reference Citation Analysis]
179 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
180 Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, Pfaender S, Balkema-Buschmann A, Dobbelstein M. Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience 2022;:104293. [PMID: 35492218 DOI: 10.1016/j.isci.2022.104293] [Reference Citation Analysis]
181 Li J, Xu J, Wang Y, Li Q, Sun X, Fu W, Zhang B. Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population. Genet Test Mol Biomarkers 2022;26:255-62. [PMID: 35638911 DOI: 10.1089/gtmb.2021.0181] [Reference Citation Analysis]
182 Mak L, Seto W, Yuen M. Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. Curr Hepatology Rep 2019;18:503-11. [DOI: 10.1007/s11901-019-00494-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Zhu B, Lv X, Zhao Z, Chen L, Chen X, Li C, Li S, Dai E. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus. Medicine (Baltimore) 2021;100:e27695. [PMID: 34871254 DOI: 10.1097/MD.0000000000027695] [Reference Citation Analysis]
184 Zeng S, Liu Y, Jiang C, Li B, Wen L, Feng Q. Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e22692. [PMID: 33031339 DOI: 10.1097/MD.0000000000022692] [Reference Citation Analysis]
185 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
186 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
188 Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori SI, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, Mitsuya H. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e02143-18. [PMID: 30670420 DOI: 10.1128/AAC.02143-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
189 Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, Sinn DH, Tanaka Y, Wai-Sun Wong V, Yuen MF. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther 2020;52:1540-50. [PMID: 32951256 DOI: 10.1111/apt.16097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
190 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res 2020;286:198040. [PMID: 32479976 DOI: 10.1016/j.virusres.2020.198040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
192 Pollicino T, Caminiti G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses 2021;13:368. [PMID: 33652619 DOI: 10.3390/v13030368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
193 Xun Z, Liu C, Yu QQ, Lin JP, Huang JL, Yang TW, Wu WN, Wu SH, Ou QS. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Clin Chim Acta 2020;502:120-7. [PMID: 31891671 DOI: 10.1016/j.cca.2019.12.020] [Reference Citation Analysis]
194 Ahodantin J, Lekbaby B, Bou Nader M, Soussan P, Kremsdorf D. Hepatitis B virus X protein enhances the development of liver fibrosis and the expression of genes associated with epithelial-mesenchymal transitions and tumor progenitor cells. Carcinogenesis 2020;41:358-67. [PMID: 31175830 DOI: 10.1093/carcin/bgz109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
195 Han JJ, Chen Y, Nan YC, Yang YL. Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report. World J Clin Cases 2021; 9(28): 8492-8497 [PMID: 34754858 DOI: 10.12998/wjcc.v9.i28.8492] [Reference Citation Analysis]
196 Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol 2021; 27(9): 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
197 Haga H, Saito T, Okumoto K, Tomita K, Katsumi T, Mizuno K, Nishina T, Watanabe H, Ueno Y. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term. J Viral Hepat 2019;26:866-72. [PMID: 30924226 DOI: 10.1111/jvh.13099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
198 Le C, Sirajee R, Steenbergen R, Joyce MA, Addison WR, Tyrrell DL. In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide. Viruses 2021;13:97. [PMID: 33445753 DOI: 10.3390/v13010097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
199 Lv X, Xiang X, Wu Y, Liu Y, Xu R, Xiang Q, Lai G. GATA binding protein 4 promotes the expression and transcription of hepatitis B virus by facilitating hepatocyte nuclear factor 4 alpha in vitro. Virol J 2021;18:196. [PMID: 34583732 DOI: 10.1186/s12985-021-01668-z] [Reference Citation Analysis]
200 Xia C, Tang W, Geng P, Zhu H, Zhou W, Huang H, Zhou P, Shi X. Baicalin down-regulating hepatitis B virus transcription depends on the liver-specific HNF4α-HNF1α axis. Toxicol Appl Pharmacol 2020;403:115131. [PMID: 32687838 DOI: 10.1016/j.taap.2020.115131] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
201 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
202 Guan G, Zheng L, Xi J, Yang X, Chen X, Lu F. Cell Cycle Arrest Protein CDKN2C Is Not an HBV Host Factor. Virol Sin 2021;36:810-3. [PMID: 33400093 DOI: 10.1007/s12250-020-00337-9] [Reference Citation Analysis]
203 Maraolo AE. Choosing the appropriate pharmacotherapy for hepatitis B during pregnancy: what are the considerations? Expert Opin Pharmacother 2021;22:1083-6. [PMID: 33797300 DOI: 10.1080/14656566.2021.1909571] [Reference Citation Analysis]
204 Guo X, Sun M, Gao R, Qu A, Chen C, Xu C, Kuang H, Xu L. Ultrasmall Copper (I) Sulfide Nanoparticles Prevent Hepatitis B Virus Infection. Angew Chem Int Ed Engl 2021;60:13073-80. [PMID: 33837622 DOI: 10.1002/anie.202103717] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
205 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
206 Macías-díaz JE, Ahmed N, Rafiq M. Analysis and Nonstandard Numerical Design of a Discrete Three-Dimensional Hepatitis B Epidemic Model. Mathematics 2019;7:1157. [DOI: 10.3390/math7121157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
207 Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020;51:231-243. [PMID: 31840863 DOI: 10.1111/apt.15581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
208 Cao Z, Liu Y, Wang S, Lu X, Yin S, Jiang S, Chen L, Cai M, Zeng B, Yao Y, Tang W, Zhao G, Xiang X, Wang H, Cai W, Zhu C, Li H, Xie Q. The impact of HBV flare on the outcome of HBV-related decompensated cirrhosis patients with bacterial infection. Liver Int. 2019;39:1943-1953. [PMID: 31206235 DOI: 10.1111/liv.14176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
209 Vinhaes CL, Cruz LAB, Menezes RC, Carmo TA, Arriaga MB, Queiroz ATL, Barral-Netto M, Andrade BB. Chronic Hepatitis B Infection Is Associated with Increased Molecular Degree of Inflammatory Perturbation in Peripheral Blood. Viruses 2020;12:E864. [PMID: 32784775 DOI: 10.3390/v12080864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Gao R, Li Y, Cao Y, Zheng R, Tang L, Yang J, Lu X. Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20604. [PMID: 32569189 DOI: 10.1097/MD.0000000000020604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
211 Huang X, Zheng X, Shen C. Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus. Evid Based Complement Alternat Med 2021;2021:2884151. [PMID: 34764998 DOI: 10.1155/2021/2884151] [Reference Citation Analysis]
212 Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Martinez SF, Weber J, Gainor E, Miller V. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.020] [Reference Citation Analysis]
213 Zakrzewicz D, Geyer J. Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery. Biomedicines 2022;10:196. [DOI: 10.3390/biomedicines10010196] [Reference Citation Analysis]
214 Vural H, Kaya M. Prediction of new potential associations between LncRNAs and environmental factors based on KATZ measure. Comput Biol Med 2018;102:120-5. [PMID: 30268976 DOI: 10.1016/j.compbiomed.2018.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
215 Xiang H, Chen Y, Zhang J, Zhang J, Pan D, Liu B, Ouyang L. Discovery of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor: Design, synthesis, and anti-proliferative activities. Chinese Chemical Letters 2020;31:1422-6. [DOI: 10.1016/j.cclet.2020.03.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
216 Zhang M, Li L, Wu L, Zhang J. Isarubrolone C Promotes Autophagic Degradation of Virus Proteins via Activating ATG10S in HepG2 Cells. J Nat Prod 2022. [PMID: 35201775 DOI: 10.1021/acs.jnatprod.1c01161] [Reference Citation Analysis]
217 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535 [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
218 Mak LY, Seto WK, Fung J, Yuen MF. New Biomarkers of Chronic Hepatitis B. Gut Liver. 2019;13:589-595. [PMID: 30919601 DOI: 10.5009/gnl18425] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
219 Hoogeveen RC, Boonstra A. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. Front Immunol 2020;11:401. [PMID: 32194573 DOI: 10.3389/fimmu.2020.00401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
220 Spitz N, Mello FCA, Moreira AS, Gusatti CS, Martins RMB, Gomes SA, Bello G, Araujo NM. Reconstruction of the spatial and temporal dynamics of hepatitis B virus genotype D in the Americas. PLoS One 2019;14:e0220342. [PMID: 31344111 DOI: 10.1371/journal.pone.0220342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
221 Chen Y, Wei D, Deng M. Comparative Analysis of Serum Proteins Between Hepatitis B Virus Genotypes B and C Infection by DIA-Based Quantitative Proteomics. Infect Drug Resist 2021;14:4701-15. [PMID: 34795487 DOI: 10.2147/IDR.S335666] [Reference Citation Analysis]
222 Gane E, Yuen MF, Kim DJ, Chan HL, Surujbally B, Pavlovic V, Das S, Triyatni M, Kazma R, Grippo JF, Buatois S, Lemenuel-Diot A, Krippendorff BF, Mueller H, Zhang Y, Kim HJ, Leerapun A, Lim TH, Lim YS, Tanwandee T, Kim W, Cheng W, Hu TH, Wat C. Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. Hepatology 2021;74:1795-808. [PMID: 34037271 DOI: 10.1002/hep.31920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
223 Kuhns MC, Holzmayer V, Anderson M, McNamara AL, Sauleda S, Mbanya D, Duong PT, Dung NTT, Cloherty GA. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen. Viruses 2021;13:2053. [PMID: 34696483 DOI: 10.3390/v13102053] [Reference Citation Analysis]
224 Alshabi A, Fatima N, Marwan A, Oraibi KG, Qubaisi EA, Arif HO, Daghriri EM, Zelai NA, Ali Khan I. Epidemiology screening and genotyping analysis for Hepatitis B virus in Southwestern region of Saudi Arabia. J Infect Public Health 2021;14:187-92. [PMID: 33486374 DOI: 10.1016/j.jiph.2020.11.016] [Reference Citation Analysis]
225 Zhao XA, Wang J, Liu J, Chen G, Yan X, Jia B, Yang Y, Liu Y, Gu D, Zhang Z, Xiang X, Huang R, Wu C. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment. Antiviral Res 2021;193:105146. [PMID: 34314774 DOI: 10.1016/j.antiviral.2021.105146] [Reference Citation Analysis]
226 Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Reference Citation Analysis]
227 Suresh M, Li B, Murreddu MG, Gudima SO, Menne S. Involvement of Innate Immune Receptors in the Resolution of Acute Hepatitis B in Woodchucks. Front Immunol 2021;12:713420. [PMID: 34367179 DOI: 10.3389/fimmu.2021.713420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Vanwolleghem T, Adomati T, Van Hees S, Janssen HL. Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. JHEP Reports 2022;4:100398. [DOI: 10.1016/j.jhepr.2021.100398] [Reference Citation Analysis]
229 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
230 Cao D, Ge JY, Wang Y, Oda T, Zheng YW. Hepatitis B virus infection modeling using multi-cellular organoids derived from human induced pluripotent stem cells. World J Gastroenterol 2021; 27(29): 4784-4801 [PMID: 34447226 DOI: 10.3748/wjg.v27.i29.4784] [Reference Citation Analysis]
231 Zhang X, Su H, Yu H, Ding J, Deng W, Qin B, Zhou C, Dou J, Guo M. A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo. Front Pharmacol 2022;13:827128. [DOI: 10.3389/fphar.2022.827128] [Reference Citation Analysis]